Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that physician-owned practices supported by its Nevada management services subsidiary have received in-network status with multiple commercial insurers and participating status with Medicare in Las Vegas. The company also initiated legacy cost reductions, estimating approximately $4.0 million in annualized expense savings to lower cash burn and support a goal of becoming cash flow positive in fiscal 2026.
Vivos said the insurer network expansion should materially increase patient access and management services revenue, while workforce and vendor changes relate to shifting from a dental distribution model to a medical affiliation model.
Positive
- $4.0M estimated annual expense savings from legacy cost reductions
- Supported practices achieved in-network and Medicare participating status in Las Vegas
- Increased patient access with thousands of previously evaluated patients reachable for coverage
Negative
- Reduction in force and vendor terminations related to legacy model
- Actual savings may vary from the $4.0M annualized estimate
- Not all supported providers are yet in-network with every payer
Key Figures
Market Reality Check
Peers on Argus
Pre-news, VVOS was down 0.87% while the only peer in the momentum scan (TRIB) was up 3.23% and broader close peers like ADGM, NSYS, and IRIX showed mixed but mostly negative moves. This points to stock-specific dynamics rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Clinical study update | Positive | +1.5% | Peer-reviewed study linking oral anatomy metrics to OSA severity and Vivos devices. |
| Feb 05 | Strategic collaboration | Positive | +0.0% | Collaboration with SoundHealth to distribute FDA-cleared allergy and sleep devices. |
| Jan 20 | Warrant exercise closing | Negative | -7.1% | Closing of warrant exercises generating $4.64M gross proceeds and new warrants issuance. |
| Jan 16 | Warrant inducement | Negative | -3.3% | Agreement for immediate warrant exercise at reduced prices with new inducement warrants. |
| Dec 16 | New sleep center | Positive | +0.0% | Opening of affiliated sleep testing and treatment center in Auburn Hills, Michigan. |
Positive strategic or clinical headlines have sometimes produced modest gains but also flat reactions, while financing-related dilution news has aligned with notable declines.
Over the past several months, Vivos has mixed clinical, strategic, and financing catalysts. A Mar 17, 2026 study tying oral anatomy to OSA and highlighting prior 510(k) clearance saw a modest gain. A Feb 5, 2026 collaboration with SoundHealth and a Dec 16, 2025 new sleep center opening drew little price reaction. By contrast, January warrant exercises and inducement structures on Jan 16 and Jan 20, 2026 coincided with clear declines. Today’s Nevada insurance-coverage and cost-cut announcement fits the strategic shift toward sleep-center and medical-affiliation models seen in prior updates.
Regulatory & Risk Context
An effective S-3 shelf dated Feb 13, 2026 covers 3,964,712 warrant shares at $2.09. The company is not selling shares under this resale registration but could receive up to $8.29 million in cash if the associated warrants are fully exercised.
Market Pulse Summary
This announcement highlights two key themes: expanded insurance and Medicare access for Vivos’ OSA treatments in the Las Vegas market, and an estimated $4 million in annualized savings from cost reductions tied to its legacy dental-focused model. Together, these moves support the pivot toward a medical affiliation distribution strategy. In the background, a recent S-3 resale registration tied to up to $8.29 million in potential warrant proceeds and prior operating losses remain important context for assessing future updates.
Key Terms
obstructive sleep apnea medical
OSA medical
CPAP medical
Medicare regulatory
TRICARE regulatory
AI-generated analysis. Not financial advice.
Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage
Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model
LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by the Company’s wholly-owned management services subsidiary in Nevada have received notices of ‘in-network’ status with a number of commercial health insurance payers, along with ‘participating’ status with Medicare.
Vivos believes this major development has the potential to positively and significantly impact patient access to Vivos’ patented OSA treatments and resulting top-line revenue and overall profitability from operations in its key treatment market of Las Vegas, NV.
In-Network Insurance Coverage
The physician-owned professional practices supported by Vivos’ management services subsidiary in Nevada report ‘in-network’ status with the following health insurance payers: Medicare, TRICARE, UnitedHealthcare, UMR, Intermountain Health, Select Health, CareSource, USDOL (workman’s comp), Anthem, Aetna, Cigna, Health Plan of Nevada, HPN Medicaid, Humana, Molina, Prominence, SilverSummit, and Wellcare, among others. The listed payers collectively cover a substantial portion of the insured population in the greater Las Vegas metropolitan area, representing what Vivos believes to be a significant addressable patient population for Vivos treatment.
Kirk Huntsman, CEO of Vivos, said, “Being ‘in-network’ with these health insurance companies and ‘participating’ status with Medicare are key milestones for the physician-owned professional practices we support, with the potential to significantly impact our management services revenue as more patients gain access to our novel OSA treatments. Since our affiliation with Sleep Center of Nevada last June, we have been working diligently to achieve insurance coverage. And while further work remains to be done in this area, as not all supported providers are ‘in-network’ with all payers, these developments are highly material to our going forward plan. Equally important, for the first time, the supported practices now have adequate numbers of trained providers to handle the expected increase in demand.”
"Previously, many OSA patients who were excited about Vivos treatment as an alternative to CPAP were denied coverage by their insurance company or Medicare. Some patients paid out of pocket or with third party patient financing, but many excellent candidates for OSA treatment were simply unable to proceed due to lack of insurance coverage. The professional practices we support have thousands of previously evaluated patients who can now be contacted regarding the availability of insurance coverage for treatment. Moreover, medical referrals are expected to rise as word spreads that insurance coverage is now available to many more OSA patients seeking Vivos treatment," concluded Mr. Huntsman.
Cost Reduction Initiatives
In addition, Vivos today announced the execution of a series of cost reduction initiatives, including a reduction in force and the termination or restructuring of a number of vendor relationships. These cost reduction initiatives, which began in February 2026, relate to Vivos' legacy dental-focused distribution model. Based on annualized run-rate calculations, Vivos estimates that these initiatives will result in approximately
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” “is expected to,” and variations of such words and similar expressions are intended to identify forward-looking statements.
In this press release, forward-looking statements include, without limitation, those relating to: the anticipated future impact on the Company's management services revenue and profitability from the affiliated practices' in-network insurance status; the estimated annual expense savings from the Company's cost reduction initiatives, including the assumption that such savings will approximate
These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to effectively market or sell products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing, and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices or enter into management services support affiliations on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) the risk that actual cost savings from cost reduction initiatives may be less than estimated or may be offset by transition costs, severance obligations, or operational disruptions, (vi) the risk that in-network status may be modified, terminated, or subject to reimbursement rate changes by insurers, (vii) the risk that patient volume increases may not materialize at the pace or magnitude anticipated, (viii) market and other conditions that could impact Vivos’ business or ability to obtain financing; and (ix) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
FAQ
What insurers granted in-network status to Vivos-supported practices in Las Vegas (VVOS) on March 26, 2026?
How much annual cost savings did Vivos (VVOS) announce on March 26, 2026 from its cost reduction initiatives?
What impact does in-network status have on Vivos Therapeutics (VVOS) revenue and patient access?
Why did Vivos (VVOS) implement reductions in force and vendor restructurings in early 2026?
Will Vivos (VVOS) become cash flow positive in 2026 after the March 26, 2026 announcement?
